NovaBay Tax Provision from 2010 to 2024

NBY Stock  USD 0.13  0.01  7.50%   
NovaBay Pharmaceuticals Tax Provision yearly trend continues to be fairly stable with very little volatility. Tax Provision will likely drop to 0.00 in 2024. Tax Provision is the amount set aside by NovaBay Pharmaceuticals to cover any estimated taxes for the current period. It reflects NovaBay Pharmaceuticals' expected tax liabilities. View All Fundamentals
 
Tax Provision  
First Reported
2010-12-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NovaBay Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NovaBay main balance sheet or income statement drivers, such as Depreciation And Amortization of 351 K, Other Operating Expenses of 16.9 M or Research Development of 64.6 K, as well as many exotic indicators such as Price To Sales Ratio of 0.0555, Dividend Yield of 0.0 or PTB Ratio of 0.25. NovaBay financial statements analysis is a perfect complement when working with NovaBay Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various NovaBay Pharmaceuticals Technical models . Check out the analysis of NovaBay Pharmaceuticals Correlation against competitors.
For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

Latest NovaBay Pharmaceuticals' Tax Provision Growth Pattern

Below is the plot of the Tax Provision of NovaBay Pharmaceuticals over the last few years. It is the amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities. NovaBay Pharmaceuticals' Tax Provision historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NovaBay Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Tax Provision10 Years Trend
Slightly volatile
   Tax Provision   
       Timeline  

NovaBay Tax Provision Regression Statistics

Arithmetic Mean6,400
Geometric Mean0.00
Coefficient Of Variation78.75
Mean Deviation4,480
Median5,000
Standard Deviation5,040
Sample Variance25.4M
Range12K
R-Value(0.88)
Mean Square Error6M
R-Squared0.78
Significance0.000012
Slope(996.43)
Total Sum of Squares355.6M

NovaBay Tax Provision History

2022null
2020 5000.0
2019 6000.0
2018 4000.0
2017 3000.0
2016 2000.0

About NovaBay Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include NovaBay Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. NovaBay Pharmaceuticals investors use historical funamental indicators, such as NovaBay Pharmaceuticals's Tax Provision, to determine how well the company is positioned to perform in the future. Although NovaBay Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in NovaBay Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on NovaBay Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on NovaBay Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in NovaBay Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Tax ProvisionK0.0

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether NovaBay Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NovaBay Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novabay Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novabay Pharmaceuticals Stock:
Check out the analysis of NovaBay Pharmaceuticals Correlation against competitors.
For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.
Note that the NovaBay Pharmaceuticals information on this page should be used as a complementary analysis to other NovaBay Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for NovaBay Stock analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
CEOs Directory
Screen CEOs from public companies around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Commodity Directory
Find actively traded commodities issued by global exchanges
Is NovaBay Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NovaBay Pharmaceuticals. If investors know NovaBay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NovaBay Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.96)
Revenue Per Share
3.494
Quarterly Revenue Growth
0.023
Return On Assets
(0.25)
Return On Equity
(1.39)
The market value of NovaBay Pharmaceuticals is measured differently than its book value, which is the value of NovaBay that is recorded on the company's balance sheet. Investors also form their own opinion of NovaBay Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is NovaBay Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NovaBay Pharmaceuticals' market value can be influenced by many factors that don't directly affect NovaBay Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NovaBay Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if NovaBay Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NovaBay Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.